Tempus AI

Calgary – September 29, 2026 -- Providence Therapeutics Holdings, Inc. has formed its first Clinical Advisory Board to guide development of its therapeutic mRNA cancer vaccine programs, including a personalized vaccine for pediatric brain cancer and off-the-shelf precision therapies for solid tumors.

Chief Medical Officer Leon Rozen chairs new four-member advisory panel

Dr. Rozen leads the board, which brings in Ezra Cohen, MD; Melinda Merchant, MD, PhD; and John Powderly, MD, to steer clinical strategy for the company's cancer vaccine pipeline.

Tempus AI oncology chief joins board with immunotherapy track record

Ezra Cohen currently serves as Chief Medical Officer for Oncology at Tempus AI. He previously held roles as Professor of Medicine and Division Chief of Hematology/Oncology at the Moores Cancer Center, University of California, San Diego.

Guangzhou – September 25, 2026 -- Pomdoctor Limited (NASDAQ: POM) outlined a differentiated "hardware plus AI plus payment" infrastructure model that it says sets the company apart from traditional internet healthcare platforms, which typically operate in silos around discrete services such as online consultations or pharmaceutical transactions.

Pomdoctor targets full-cycle predictive healthcare integration

The Guangzhou-based digital healthcare company said its system is designed to combine continuous health monitoring, AI-powered analysis, physician intervention, healthcare payment and fulfillment into a single closed-loop ecosystem, rather than offering standalone services.

Morristown, N.J. – September 17, 2026 -- Whitehawk Therapeutics (Nasdaq: WHWK) presented real-world data at the IASLC 2026 World Conference on Lung Cancer in Seoul showing that PTK7 expression remains stable in pretreated, EGFR wild-type non-small cell lung cancer (NSCLC), reinforcing the target biology behind its Phase 1 antibody-drug conjugate (ADC) HWK-007.